IG Utilization Updates At A Glance
Attachment(s)
Recommended Indications in which IG can be used
Order Number: N1-ADEM
Recommendations | IVIG is recommended for:
|
Dose/Frequency of Administration | Induction: 2 g/kg adjusted body weight divided over 2 to 5 days. Maintenance (for recurrent or multiphasic ADEM only): 0.4 to 2 g/kg adjusted body weight every 4 to 6 weeks. Once the patient’s condition has stabilized, consider titrating the dose and/or the treatment interval to the lowest dose necessary to maintain clinical effectiveness. |
Attachment(s)
Do Not Use
For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.
Recommendations | IG is not recommended |
Attachment(s)
Do Not Use
For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.
Recommendations | IG is not recommended |
Attachment(s)
Do Not Use
For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.
Recommendations | IG is not recommended |
Attachment(s)
Do Not Use
For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.
Recommendations | IG is not recommended |
Attachment(s)
Not for Routine Use
When screening requests for approval, the following information may be taken into account as there is some evidence for IG to be considered as an option.
Order Number: H14-AH
Recommendations | Not recommended for routine use. IVIG may be considered one option among adjunctive therapies, such as steroids, in urgent situations. Prescribed only in consultation with specialized hemophilia care centre. |
Dose/Frequency of Administration | Up to a total of 2 g/kg divided over 2 to 5 consecutive days, for short term use. |
Attachment(s)
Includes but not limited to:
- Encephalitis associated with antibodies to: NMDA receptor, VGKC, LGI1, CASPR2, DPPX, AMPA receptor, glycine receptor, or GABA (A or B) receptor.
- Highly suspected autoimmune encephalitis
- Paraneoplastic encephalitis
- Seronegative autoimmune encephalitis
- Seronegative limbic encephalitis
- Suspected autoimmune limbic encephalitis
(See separate entry for Rasmussen syndrome)
Recommended Indications in which IG can be used
Order Number: N2-AMAE
Recommendations | IVIG may be used as an option with expert consultation. |
Dose/Frequency of Administration | Induction: 2 g/kg adjusted body weight divided over 2 to 5 days. Maintenance: 0.5 to 2 g/kg adjusted body weight monthly, if necessary. |
Attachment(s)
Not for Routine Use
When screening requests for approval, the following information may be taken into account as there is some evidence for IG to be considered as an option.
Order Number: H15-ARCA
Recommendations | IVIG is an option for patients with immunologic pure red cell aplasia (PRCA) who have failed other therapies (e.g., prednisone or cyclosporin). IVIG should be considered first-line therapy for viral PRCA associated with parvovirus B19 in immunocompromised patients. See separate entry Parvovirus B19 in solid organ transplant recipients. |
Dose/Frequency of Administration | Up to 2 g/kg divided over 2 to 5 consecutive days for short term use. Repeat on relapse. |
Attachment(s)
(See separate entry for Demyelinating neuropathy associated with IgM paraproteinemia, without anti-MAG antibodies)
Do Not Use
For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.
Recommendations | Recommendation includes but is not limited to:
|